Senetek discontinues Alzheimer's diagnosis research
This article was originally published in Clinica
Executive Summary
UK company Senetek has discontinued development of a monoclonal antibody-based test for early diagnosis of Alzheimer's disease. However, it plans to begin sales of certain cell lines capable of producing monoclonal antibodies, including those applicable to Alzheimer's disease, for diagnostic and research purposes. The cell lines are licensed exclusively from the Research Foundation for Mental Hygiene.